Abbott Laboratories is a global healthcare company that specializes in the development of a wide range of medical devices, diagnostics, nutrition products, and pharmaceuticals
The company focuses on innovation to improve patient outcomes and enhance the quality of life for individuals worldwide. Abbott is known for its advancements in areas such as cardiovascular care, diabetes management, and nutrition science, providing essential tools and solutions that support healthcare professionals and patients in managing various health conditions. With a strong commitment to research and development, Abbott continually seeks to address unmet medical needs and contribute to the advancement of healthcare globally.
AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified stocks, starting with Stryker (NYSESYK).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4, starting with Baxter (NYSEBAX).
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQNEOG) and its peers.
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts highlighted long-term growth potential.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSEBSX) and the best and worst performers in the medical devices & supplies - diversified industry.
Pharmaceutical company AbbVie (NYSEABBV) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share was 4.3% below analysts’ consensus estimates.
Healthcare product and device company Abbott Laboratories (NYSEABT) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.2% year on year to $10.97 billion. Its non-GAAP profit of $1.34 per share was in line with analysts’ consensus estimates.
